Singapore, Aug. 12 -- South Korea based Biostar Stem Cell Technology Research Institute, led by Director Jeong Chan Ra, and jointly operated by R BIO and Nature Cell, has announced that its regenerative autism treatment has been officially approved by the Japanese Ministry of Health, Labour and Welfare.

The approved therapy, which uses autologous fat-derived mesenchymal stem cells, will be offered at Osaka Trinity Clinic, a Biostar-affiliated medical centre.

With this approval, patients diagnosed with autism spectrum disorder (ASD) aged four or older are now eligible to receive regenerative treatment at Osaka Trinity Clinic. The treatment involves 50 million to 300 million stem cells intravenously, administered over 5 to 10 sessions, 2 ...